A Longitudinal Study of the Effects of Lithium Treatment on Prefrontal and Subgenual Prefrontal Gray Matter Volume in Treatment-Responsive Bipolar Disorder Patients

Moore, Gregory J.; Cortese, Bernadette M.; Glitz, Debra; Zajac-Benitez, Caroline; Quiróz, Jorge A.; Uhde, Thomas W.; Drevets, Wayne C.; Manji, Husseini K.

doi:10.4088/jcp.07m03745

Cited by 209 publications

(129 citation statements)

References 0 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…One study revealed that a favorable clinical response in BP was associated with persistently increased cerebral gray matter volume over the course of 16 weeks of treatment [Lyoo et al 2010]. A second studied 28 patients with BP longitudinally for 4 weeks and determined that patients who responded to lithium had increased prefrontal gray matter compared with those who did not respond [Moore et al 2009]. …”

Section: Bipolar Disordermentioning

confidence: 99%

Predictors of lithium response in bipolar disorder

Tighe

Mahon

Potash

2011

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

While lithium is generally regarded as the first-line agent for patients with bipolar disorder, it does not work for everyone, which raises the question: can we predict who will be most likely to respond? In this paper, we review the most compelling clinical, biologic, and genetic predictors of lithium response in bipolar disorder. Among clinical factors, the strongest predictors of good response are fewer hospitalizations preceding treatment, an episodic course characterized by an illness pattern of mania followed by depression, and a later age at onset of bipolar disorder. While several biologic predictors have been studied, the results are preliminary and require replication with studies of larger patient samples over longer observation periods. Neuroimaging is a particularly promising method given that it might concurrently illuminate pathophysiologic underpinnings of bipolar disorder, the mechanism of action of lithium, and potential predictors of lithium response. The first genome-wide association study of lithium response was recently completed. No definitive results emerged, perhaps because the study was underpowered. With major new initiatives in progress aiming to identify genes and genetic variations associated with lithium response, there is much reason to be hopeful that clinically useful information might be generated within the next several years. This could ultimately translate into tests that could guide the choice of mood-stabilizing medication for patients. In addition, it might facilitate pharmacologic research aimed at developing newer, more effective medications that might act more quickly and yield fewer side effects.

show abstract

Section: Bipolar Disordermentioning

confidence: 99%

Predictors of lithium response in bipolar disorder

Tighe

Mahon

Potash

2011

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…Lithium may counteract some of these deficits via its neurotrophic effects; for example, it has been shown to affect brain derived neurotrophic factor (BDNF) levels in individuals with BD (Suwalska et al, 2010;de Sousa et al, 2011). In addition, lithium treatment has been shown to increase gray matter volume in patients with BD in whole brain, cortex, hippocampus, and anterior cingulate (Sassi et al, 2002;Bearden et al, 2007Bearden et al, , 2008Moore et al, 2000bMoore et al, , 2009). Lithium also increases brain volume in limbic structures, such as the hippocampus (Yucel et al, 2007(Yucel et al, , 2008, that are implicated in emotional regulation.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Potential of Mood Stabilizers Lithium and Valproic Acid: Beyond Bipolar Disorder

et al. 2013

View full text Add to dashboard Cite

“…In keeping with this, Li slowed the decline in cognitive performance and decreased the levels of phosphorylated tau protein in patients with amnestic mild cognitive impairment. 60 Arguing for the indirect, clinically mediated effect are studies showing that grey matter volume increases after treatment with Li were only detected among responders, but not nonresponders, to treatment 61 and were associated with clinical improvement. 62 Thus, both the direct neurochemical effects and the indirect effects through the treatment/ prevention of episodes of illness likely underlie the larger grey matter volumes in Li-treated patients.…”

mentioning

confidence: 99%